At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Our scientific leadership and broad platform have enabled us to produce a rich pipeline of important new medicines for rare blood disorders, neuromuscular, and pulmonary diseases.
- We are developing luspatercept-aamt, our lead product candidate, for the treatment of the chronic anemias in myelodysplastic syndromes (MEDALIST Phase 3 and COMMANDS Phase 3 trials ongoing), beta-thalassemia (BELIEVE Phase 3 and BEYOND Phase 2 trials ongoing), and myelofibrosis (Phase 2 trial ongoing). The goal of these trials is to reduce or eliminate the need for regular red blood cell transfusions. Luspatercept-aamt is currently under a global partnership with Bristol Myers Squibb.
- ACE-083 is being studied in two, two-part Phase 2 trials; one trial is being conducted in facioscapulohumeral muscular dystrophy (FSHD) and the other is being conducted in Charcot-Marie-Tooth (CMT) disease.
- In our pulmonary program, our newest disease focus area, we have initiated the PULSAR and SPECTRA Phase 2 trials in pulmonary arterial hypertension (PAH).
The clinical trials listed below are Acceleron or partner-sponsored trials that are actively recruiting patients. Each trial in the list contains a link to clinicaltrials.gov, where you will find a full description and contact information.